Erlotinib Preserves Renal Function and Prevents Salt Retention in Doxorubicin Treated Nephrotic Rats

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bou Matar, Raed N ^a   Klein, Janet D ^a,b   Sands, Jeff M ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL SODIUM CHANNEL; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; SODIUM; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SODIUM POTASSIUM CHLORIDE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; NEPHROSIS; NEPHROTIC SYNDROME; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RECEPTOR BLOCKING; SODIUM RETENTION; SODIUM URINE LEVEL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AQUAPORIN 2; CREATININE; DOXORUBICIN; EPITHELIAL SODIUM CHANNELS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEPHROTIC SYNDROME; PROTEIN KINASE INHIBITORS; PROTEINURIA; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RENAL INSUFFICIENCY; SODIUM CHLORIDE SYMPORTERS; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS;

RATTUS;

EID: 84872526100     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054738     Document Type: Article

References (32)

1. Kitiyakara C, Kopp JB, Eggers P, (2003) Trends in the epidemiology of focal segmental glomerulosclerosis. Seminars in Nephrology 23: 172-182.
2. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, et al. (2008) Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev: CD003233.
3. Paizis K, Kirkland G, Polihronis M, Katerelos M, Kanellis J, et al. (1998) Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney Int 53: 1162-1171.
4. Khong TF, Fraser S, Katerelos M, Paizis K, Hill PA, et al. (2000) Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis. Kidney Int 58: 1098-1107.
5. Lee YJ, Shin SJ, Lin SR, Tan MS, Tsai JH, (1995) Increased Expression of Heparin Binding Epidermal-Growth Factor-like Growth Factor mRNA in the Kidney of Streptozotocin-Induced Diabetic Rats. Biochemical and Biophysical Research Communications 207: 216-222.
6. Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, et al. (2011) Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17: 1242-1250.
7. Feng L, Garcia GE, Yang Y, Xia Y, Gabbai FB, et al. (2000) Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats. The Journal of Clinical Investigation 105: 341-350.
8. Sakai M, Zhang M, Homma T, Garrick B, Abraham JA, et al. (1997) Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules. The Journal of Clinical Investigation 99: 2128-2138.
9. Raymond E, Faivre S, Armand JP, (2000) Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy. Drugs 60: 15-23.
10. Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, et al. (2011) Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4. Cancer Research 71: 3932-3940.
11. Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, et al. (2010) Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). The Oncologist 15: 1344-1351.
12. Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, et al. (2012) Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets 13: 802-810.
13. Mok TSK, Wu Y-L, Yu C-J, Zhou C, Chen Y-M, et al. (2009) Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 27: 5080-5087.
14. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, et al. (2004) Determinants of Tumor Response and Survival With Erlotinib in Patients With Non - Small-Cell Lung Cancer. Journal of Clinical Oncology 22: 3238-3247.
15. Wassef L, Kelly DJ, Gilbert RE, (2004) Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 66: 1805-1814.
16. Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, et al. (2011) Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology 16: 573-581.
17. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, et al. (1986) Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 29: 502-510.
18. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, et al. (2009) Inducible rodent models of acquired podocyte diseases. American Journal of Physiology - Renal Physiology 296: F213-F229.
19. Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, et al. (2009) Plasmin in Nephrotic Urine Activates the Epithelial Sodium Channel. Journal of the American Society of Nephrology 20: 299-310.
20. Svenningsen P, Uhrenholt TR, Palarasah Y, Skjødt K, Jensen BL, et al. (2009) Prostasin-dependent activation of epithelial Na+ channels by low plasmin concentrations. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 297: R1733-R1741.
21. Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, et al. (2008) Plasmin Activates Epithelial Na+ Channels by Cleaving the γ Subunit. Journal of Biological Chemistry 283: 36586-36591.
22. Bou Matar RN, Malik B, Wang XH, Martin CF, Eaton DC, et al. (2012) Protein abundance of urea transporters and aquaporin 2 change differently in nephrotic pair-fed vs. non-pair-fed rats. Am J Physiol Renal Physiol 302: F1545-1553.
23. Agarwal R, Gorski JC, Sundblad K, Brater DC, (2000) Urinary Protein Binding Does Not Affect Response to Furosemide in Patients with Nephrotic Syndrome. Journal of the American Society of Nephrology 11: 1100-1105.
24. Liu L, Duke BJ, Malik B, Yue Q, Eaton DC, (2009) Biphasic regulation of ENaC by TGF-α and EGF in renal epithelial cells. American Journal of Physiology - Renal Physiology 296: F1417-F1427.
25. Kim D-U, Sands JM, Klein JD, (2003) Changes in renal medullary transport proteins during uncontrolled diabetes mellitus in rats. AmJPhysiolRenal Physiol 285: F303-F309.
26. Malik B, Schlanger L, Al-Khalili O, Bao H-F, Yue G, et al. (2001) ENaC degradation in A6 cells by the ubiquitin-proteosome proteolytic pathway. JBiolChem 276: 12903-12910.
27. Kim SW, Wang WD, Nielsen J, Praetorius J, Kwon TH, et al. (2004) Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. American Journal of Physiology: Renal Physiology 286: F922-F935.
28. Ecelbarger CA, Kim GH, Wade JB, Knepper MA, (2001) Regulation of the abundance of renal sodium transporters and channels by vasopressin. Experimental Neurology 171: 227-234.
29. Apostol E, Ecelbarger CA, Terris J, Bradford AD, Andrews P, et al. (1997) Reduced renal medullary water channel expression in puromycin aminonucleoside-induced nephrotic syndrome. JAmSocNephrol 8: 15-24.
30. Fernández-Llama P, Andrews P, Ecelbarger CA, Nielsen S, Knepper MA, (1998) Concentrating defect in experimental nephrotic syndrome: Altered expression of aquaporins and thick ascending limb Na+ transporters. Kidney International 54: 170-179.
31. Fernández-Llama P, Andrews P, Nielsen S, Ecelbarger CA, Knepper MA, (1998) Impaired aquaporin and urea transporter expression in rats with adriamycin-induced nephrotic syndrome. Kidney International 53: 1244-1253.
32. Kim SW, de Seigneux S, Sassen MC, Lee J, Kim J, et al. (2006) Increased apical targeting of renal ENaC subunits and decreased expression of 11βHSD2 in HgCl2-induced nephrotic syndrome in rats. American Journal of Physiology - Renal Physiology 290: F674-F687.